1
|
de Alencar MVOB, Islam MT, da Mata AMOF, Dos Reis AC, de Lima RMT, de Oliveira Ferreira JR, de Castro E Sousa JM, Ferreira PMP, de Carvalho Melo-Cavalcante AA, Rauf A, Hemeg HA, Alsharif KF, Khan H. Anticancer effects of phytol against Sarcoma (S-180) and Human Leukemic (HL-60) cancer cells. ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH INTERNATIONAL 2023; 30:80996-81007. [PMID: 37308630 DOI: 10.1007/s11356-023-28036-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 05/29/2023] [Indexed: 06/14/2023]
Abstract
Phytol (Pyt), a diterpenoid, possesses many important bioactivities. This study evaluates the anticancer effects of Pyt on sarcoma 180 (S-180) and human leukemia (HL-60) cell lines. For this purpose, cells were treated with Pyt (4.72, 7.08, or 14.16 μM) and a cell viability assay was performed. Additionally, the alkaline comet assay and micronucleus test with cytokinesis were also performed using doxorubicin (6 μM) and hydrogen peroxide (10 mM) as positive controls and stressors, respectively. Results revealed that Pyt significantly reduced the viability and rate of division in S-180 and HL-60 cells with IC50 values of 18.98 ± 3.79 and 1.17 ± 0.34 μM, respectively. Pyt at 14.16 μM exerted aneugenic and/or clastogenic effects in S-180 and HL-60 cells, where the number of micronuclei and other nuclear abnormalities (e.g., nucleoplasmic bridges and nuclear buds) were frequently observed. Moreover, Pyt at all concentrations induced apoptosis and showed necrosis at 14.16 μM, suggesting its anticancer effects on the tested cancer cell lines. Taken together, Pyt showed promising anticancer effects, possibly through inducing apoptosis and necrosis mechanisms, and it exerted aneugenic and/or clastogenic effects on the S-180 and HL-60 cell lines.
Collapse
Affiliation(s)
- Marcus Vinícius Oliveira Barros de Alencar
- Postgraduate Program in Biotechnology (RENORBIO), Federal University of Piauí, Teresina, 64.049-550, Brazil
- Biomedical Sciences Research and Innovation Laboratory, Postgraduate Program in Biotechnology, INTA University Center, Sobral, 62.011-230, Brazil
- Laboratory of Toxicological Genetics, Department of Biochemistry and Pharmacology, Federal University of Piauí, Teresina, Piauí, 64.049-550, Brazil
| | - Muhammad Torequl Islam
- Postgraduate Program in Biotechnology (RENORBIO), Federal University of Piauí, Teresina, 64.049-550, Brazil
- Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
| | - Ana Maria Oliveira Ferreira da Mata
- Postgraduate Program in Biotechnology (RENORBIO), Federal University of Piauí, Teresina, 64.049-550, Brazil
- Laboratory of Toxicological Genetics, Department of Biochemistry and Pharmacology, Federal University of Piauí, Teresina, Piauí, 64.049-550, Brazil
| | - Antonielly Campinho Dos Reis
- Postgraduate Program in Biotechnology (RENORBIO), Federal University of Piauí, Teresina, 64.049-550, Brazil
- Laboratory of Toxicological Genetics, Department of Biochemistry and Pharmacology, Federal University of Piauí, Teresina, Piauí, 64.049-550, Brazil
| | - Rosália Maria Torres de Lima
- Postgraduate Program in Biotechnology (RENORBIO), Federal University of Piauí, Teresina, 64.049-550, Brazil
- Laboratory of Toxicological Genetics, Department of Biochemistry and Pharmacology, Federal University of Piauí, Teresina, Piauí, 64.049-550, Brazil
| | | | - João Marcelo de Castro E Sousa
- Postgraduate Program in Biotechnology (RENORBIO), Federal University of Piauí, Teresina, 64.049-550, Brazil
- Laboratory of Toxicological Genetics, Department of Biochemistry and Pharmacology, Federal University of Piauí, Teresina, Piauí, 64.049-550, Brazil
| | - Paulo Michel Pinheiro Ferreira
- Postgraduate Program in Biotechnology (RENORBIO), Federal University of Piauí, Teresina, 64.049-550, Brazil
- Laboratory of Experimental Cancerology, Department of Biophysics and Physiology, Federal University of Piauí, Teresina, 64.049-550, Brazil
| | - Ana Amélia de Carvalho Melo-Cavalcante
- Postgraduate Program in Biotechnology (RENORBIO), Federal University of Piauí, Teresina, 64.049-550, Brazil
- Laboratory of Toxicological Genetics, Department of Biochemistry and Pharmacology, Federal University of Piauí, Teresina, Piauí, 64.049-550, Brazil
| | - Abdur Rauf
- Department of Chemistry, University of Swabi, Anbar, Swabi, Khyber Pakhtunkhwa, 23430, Pakistan
| | - Hassan A Hemeg
- Department of Medical Laboratory Technology, College of Applied Medical Sciences, Taibah University, Al-Medinah Al-Monawara, 41411, Saudi Arabia
| | - Khalaf F Alsharif
- Department of Clinical Laboratory, College of Applied Medical Science, Taif University, Taif, 21944, Saudi Arabia
| | - Haroon Khan
- Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
| |
Collapse
|
2
|
Tools used to assay genomic instability in cancers and cancer meiomitosis. J Cell Commun Signal 2021; 16:159-177. [PMID: 34841477 DOI: 10.1007/s12079-021-00661-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 11/21/2021] [Indexed: 10/19/2022] Open
Abstract
Genomic instability is a defining characteristic of cancer and the analysis of DNA damage at the chromosome level is a crucial part of the study of carcinogenesis and genotoxicity. Chromosomal instability (CIN), the most common level of genomic instability in cancers, is defined as the rate of loss or gain of chromosomes through successive divisions. As such, DNA in cancer cells is highly unstable. However, the underlying mechanisms remain elusive. There is a debate as to whether instability succeeds transformation, or if it is a by-product of cancer, and therefore, studying potential molecular and cellular contributors of genomic instability is of high importance. Recent work has suggested an important role for ectopic expression of meiosis genes in driving genomic instability via a process called meiomitosis. Improving understanding of these mechanisms can contribute to the development of targeted therapies that exploit DNA damage and repair mechanisms. Here, we discuss a workflow of novel and established techniques used to assess chromosomal instability as well as the nature of genomic instability such as double strand breaks, micronuclei, and chromatin bridges. For each technique, we discuss their advantages and limitations in a lab setting. Lastly, we provide detailed protocols for the discussed techniques.
Collapse
|